Clinical Trials
FDA Approval of Keytruda® in Head and Neck Cancer Highlights Potential for Gedeptin® Combination Therapy
The FDA's approval of Keytruda® for head and neck cancer treatment underscores the therapeutic potential of combining it with GeoVax’s Gedeptin®, aiming to enhance tumor clearance and reduce relapse rates.
Medicus Pharma Ltd. Develops Novel Non-Invasive Treatment for Basal Cell Carcinoma
Medicus Pharma Ltd. is advancing a revolutionary, non-invasive microneedle patch treatment for basal cell carcinoma, potentially transforming the $15 billion skin cancer treatment market.
Soligenix's SGX302 Shows Promise in Psoriasis Treatment
Soligenix Inc.'s SGX302, a novel therapy for psoriasis, has demonstrated effectiveness and safety in Phase 2a trials, offering hope to millions affected by this autoimmune disorder.
Food Is Medicine Programs Show Promise in Improving Health Outcomes, More Research Needed
Recent findings highlight the potential of Food Is Medicine (FIM) programs to enhance diet quality and food security among individuals with chronic diseases, though further research is essential to understand their clinical impact fully.
Quantum BioPharma Ltd. Advances in Brain and Alcohol Health Research with Phase 2 Trial Approval
Quantum BioPharma Ltd. makes significant strides in its brain disorders and alcohol health pipeline, including Phase 2 trial approval for FSD202 and preparations for an IND filing for Lucid-MS, highlighting its commitment to addressing unmet medical needs.
PolyPid Secures $26.7 Million Funding, Advances Toward FDA Approval with Promising D-PLEX₁₀₀
PolyPid Ltd. has secured $26.7 million in funding following successful Phase 3 trial results for its surgical infection prevention technology, D-PLEX₁₀₀, positioning the company for FDA approval and significant market impact.
Study Reveals Unchanged Prevalence of Psoriasis in the U.S., Highlights Need for Better Treatments
A recent study published in the Journal of American Academy of Dermatology shows the prevalence of psoriasis among U.S. adults remains steady at 3% over the last decade, underscoring the ongoing need for effective treatments and improved diagnostic access.
Soligenix Advances Treatment for Behçet’s Disease with New Clinical Trial
Soligenix Inc. has initiated a clinical trial for SGX945, a potential treatment for Behçet’s disease, a rare autoimmune disorder with limited treatment options, highlighting a significant step towards addressing the unmet needs of patients globally.
Quantum BioPharma Advances MS Research with Groundbreaking PET Imaging Study
Quantum BioPharma Ltd. has initiated a pioneering PET imaging study with Massachusetts General Hospital to track myelin integrity in multiple sclerosis patients, potentially revolutionizing treatment evaluation.
GeoVax's GEO-CM04S1 Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines
GeoVax Labs, Inc. reports that its GEO-CM04S1 vaccine has demonstrated superior T cell responses in chronic lymphocytic leukemia (CLL) patients compared to an authorized mRNA COVID-19 vaccine, highlighting potential advancements in protecting immunocompromised individuals.
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections
BiomX Inc. has reported successful Phase 2 clinical trial results for treating diabetic foot bone infections and cystic fibrosis with bacteriophage therapy, offering a potential solution to the growing antibiotic resistance crisis.
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
Lantern Pharma Inc. (NASDAQ: LTRN) has reported a significant clinical outcome in its Phase 2 HARMONIC(TM) trial, showcasing the potential of its LP-300 treatment in combination with standard chemotherapy for never-smoker patients with advanced non-small cell lung cancer (NSCLC), marking a pivotal moment in oncology treatment.
Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment
Tonix Pharmaceuticals Holding Corp. has unveiled positive Phase 3 trial data for TNX-102 SL, a potential breakthrough in fibromyalgia treatment, showcasing significant pain reduction and improved sleep quality, marking a significant advancement in pain management therapies.
GeoVax Gains EMA Support for Streamlined Mpox and Smallpox Vaccine Development
GeoVax Labs, Inc. receives favorable regulatory guidance from the European Medicines Agency, simplifying the development pathway for its GEO-MVA vaccine against Mpox and smallpox, marking a significant step towards addressing global vaccine shortages.
HeartBeam Inc. Advances Toward Commercialization with Promising Q1 2025 Results
HeartBeam Inc. reports significant progress in its Q1 2025 results, including successful clinical endpoints in its VALID-ECG study and strategic collaborations, marking a pivotal step towards the commercialization of its innovative cardiac care technology.
Cybin Inc. Advances Phase 3 Psychedelic Therapeutics Program, Signaling Progress in Mental Health Treatment
Cybin Inc. reports significant progress in its Phase 3 clinical trials for CYB003, a novel treatment for major depressive disorder, highlighting the potential of psychedelic therapeutics in addressing mental health conditions.
Soligenix Inc. Advances Clinical Programs with Key Trial Results Expected by 2026
Soligenix Inc. is making significant progress in its clinical programs, with critical trial results for treatments of rare diseases like cutaneous T-cell lymphoma and Behçet’s disease expected in the coming years, highlighting the company's role in addressing unmet medical needs.
GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025
GeoVax Labs, Inc. announces its participation in the 2025 BIO International Convention, highlighting its pipeline of vaccines and immunotherapies for infectious diseases and cancer, underscoring the company's role in advancing global health solutions.
GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress
GeoVax Labs, Inc. will present clinical data at the European Hematology Association 2025 Congress, demonstrating the superior cellular immune response of its GEO-CM04S1 vaccine in chronic lymphocytic leukemia patients compared to mRNA-based vaccines.
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Biotech and Neurotrauma Events
Oragenics Inc. (NYSE American: OGEN) is set to present its intranasal neurosteroid candidate for concussion treatment, ONP-002, at two significant 2025 events, highlighting its potential impact on neurology and pharmaceutical sectors.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise Against Variants
GeoVax Labs, Inc. reports preclinical success of its multi-antigen COVID-19 vaccines, GEO-CM04S1 and GEO-CM02, in providing durable, cross-reactive immunity against SARS-CoV-2 variants, including Omicron XBB.1.5, highlighting the potential for broader protection without the need for frequent updates.
Soligenix's HyBryte(TM) Offers New Hope for CTCL Patients with FDA Orphan Drug Designation
Soligenix Inc. advances in the treatment of Cutaneous T-cell lymphoma (CTCL) with HyBryte(TM), a photodynamic therapy showing promise in clinical trials and receiving Orphan Drug Designation, addressing a critical need for effective therapies in this rare disease.
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in CMV Management for Transplant Patients
Kamada Ltd. is amplifying its commitment to organ transplant patients by enhancing awareness and research around CYTOGAM, its treatment for cytomegalovirus (CMV), a potentially deadly complication for transplant recipients.
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025
Calidi Biotherapeutics Inc. presents groundbreaking data on its lead candidate CLD-401 at the ASCO Annual Meeting, showcasing advancements in systemic oncolytic targeted immunotherapies with potential implications for cancer treatment.
CNS Pharmaceuticals Inc. to Showcase Glioblastoma Treatment Advancements at Brain Tumor Biotech Summit
CNS Pharmaceuticals Inc. will present promising data on its brain-penetrating taxane candidate, TPI 287, at the upcoming Brain Tumor Biotech Summit, highlighting potential breakthroughs in treating glioblastoma and other CNS tumors.
Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates
Annovis Bio Inc. (NYSE: ANVS) is set to host a webcast featuring CEO Maria Maccecchini, Ph.D., to discuss updates on its Phase 3 trial for early Alzheimer’s disease and FDA feedback on its Parkinson’s disease program, highlighting the company's progress in neurodegenerative disease treatments.
Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025
Tonix Pharmaceuticals Holding Corp. is set to present its latest research at the Annual European Congress of Rheumatology (EULAR) 2025, highlighting advancements in rheumatologic conditions and its broader pipeline.
Orca Bio Strengthens Leadership Team with Key Appointments Ahead of Potential Commercial Launch
Orca Bio has appointed Steve Gavel as Chief Commercial Officer and Allison Frisbee as Senior Vice President, Legal, marking a strategic move to bolster its leadership team as it prepares for the potential commercial launch of its lead investigational therapy, Orca-T®.
Kairos Pharma Ltd. Showcases Promising Preclinical Results for KROS101 at ASCO 2025
Kairos Pharma Ltd. reveals preclinical data at ASCO 2025 indicating KROS101's potential to enhance cancer immunotherapy by improving T cell activity and reducing immune suppression.
Bio-Path Holdings Advances in RNAi Therapeutics with Promising Clinical Trials
Bio-Path Holdings, Inc. makes strides in RNA interference therapeutics, with its DNAbilize® platform showing potential in treating cancers, obesity, and type 2 diabetes, marking a significant step forward in biotechnology.